Last reviewed · How we verify

Cardurion Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Cardurion Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Astellas Pharma Inc · 1 shared drug class
  3. Dr. dr. Lili Legiawati, SpKK(K) · 1 shared drug class
  4. Eurofarma Laboratorios S.A. · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Kissei Pharmaceutical Co., Ltd. · 1 shared drug class
  7. Triple Hair Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cardurion Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Cardurion Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cardurion-pharmaceuticals-inc. Accessed 2026-05-17.

Related